ArticleslgStudy

chemistry

Obeldesivir

Obeldesivir is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Obeldesivir rather than just read about it. In short: Obeldesivir (GS-5245, ATV006) is an isobutyric ester prodrug of GS-441524 made by Gilead Sciences that was evaluated in a Phase III trial for the outpatient treatment of COVID-19 in high risk patients. The purpose of the isobutyric ester modification on obeldesivir is to improve the oral bioavailability of the parent nucleoside, GS-441524.

Obeldesivir — main illustration
Obeldesivir — illustration

Key takeaways

  • Obeldesivir belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Obeldesivir to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Obeldesivir from memory before moving on to harder problems.

Reference excerpt

Obeldesivir (GS-5245, ATV006) is an isobutyric ester prodrug of GS-441524 made by Gilead Sciences that was evaluated in a Phase III trial for the outpatient treatment of COVID-19 in high risk patients. The purpose of the isobutyric ester modification on obeldesivir is to improve the oral bioavailability of the parent nucleoside, GS-441524. Obeldesivir is hydrolyzed to its parent nucleoside, GS-441524, which is in turn converted to remdesivir-triphosphate (GS-443902) by a nucleoside kinase, adenylate kinase and nucleotide diphosphate kinase. GS-443902 is a bioactive ATP analogue with broad-spectrum antiviral activity and is the same compound formed by remdesivir, though by a different enzymatic pathway. Unlike remdesivir, which is metabolized by enzymes that are highly expressed in the liver, GS-441524 released by obeldesivir is metabolized by enzymes that are evenly expressed throughout the body. Due to their different metabolic pathways, obeldesivir can be administered orally, whereas remdesivir must be administered intravenously for COVID-19 treatment. Obeldesivir has also been investigated as a potential antiviral treatment for Ebola. The pharmacokinetic properties of obeldesivir and improved was first published by Chinese researchers in May 2022. The Chinese group pursued investigation of obeldesivir independently from Gilead Sciences. Compared to IV administered GS-441524 in rats at 5 mg/kg, orally administered obeldesivir at 25 mg/kg (referred to as "ATV006") yielded approximately 22% bioavailability. Treatment with obdeldesivir reduced viral load and prevents lung pathology in KI-hACE2 and Ad5-hACE2 mouse models of SARS-CoV-2. In the recently completed randomized trial conducted among nonhospitalized adults with risk factors for developing severe COVID-19, patients were enrolled within 5 days of COVID-19 symptom onset and randomized to receive obeldesivir 350 mg or placebo twice daily for 5 days. The primary endpoint was COVID-19–related hospitalization or death due to any cause by Day 29. Other endpoints included time to symptom alleviation by Day 15, change in SARS-CoV-2 viral RNA copy number and infectious viral titer, and incidence of adverse events and laboratory abnormalities. The trial had a target sample size of 2300 participants but was halted early due to a lower-than-expected event rate for the primary endpoint. 465 participants were evaluable for safety and 418 for efficacy. 92% had serologic evidence of prior SARS-CoV-2 infection or COVID-19 vaccination, which likely explains why COVID-19–related hospitalization or death by Day 29 occurred in none of the 211 (0%) participants assigned to receive obeldesivir and only of 1 of the 207 (0.5%) assigned to placebo. Time to COVID-19 symptom alleviation was numerically shorter by 2 days with obeldesivir than with placebo, although this difference was not statistically significant. However, obeldesivir did significantly reduce viral RNA copy number at Day 5 and infectious viral titer at Days 3 and 5 compared to placebo. The safety profile was generally comparable between active drug and placebo.

References

Illustrations

Obeldesivir illustration

Worked examples

Example 1 — a first encounter with Obeldesivir

Start with the simplest possible case. Write down what Obeldesivir claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Obeldesivir before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Obeldesivir ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Obeldesivir

In research
Obeldesivir appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Obeldesivir in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Obeldesivir is common in secondary-school and first-year university syllabi. It links to neighbouring topics Anti–RNA virus drugs, Heterocyclic compounds with 2 rings, Nitriles, so understanding it makes those chapters shorter.
In everyday life
Look for Obeldesivir outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Obeldesivir” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Obeldesivir in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Obeldesivir means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Obeldesivir out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Obeldesivir in simple terms?

Obeldesivir (GS-5245, ATV006) is an isobutyric ester prodrug of GS-441524 made by Gilead Sciences that was evaluated in a Phase III trial for the outpatient treatment of COVID-19 in high risk patients. The purpose of the isobutyric ester modification on obeldesivir is to improve the oral bioavailab…

Why does Obeldesivir matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Obeldesivir?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Obeldesivir.

Tags

  • Anti–RNA virus drugs
  • Heterocyclic compounds with 2 rings
  • Nitriles
  • Nitrogen heterocycles
  • Tetrahydrofurans
  • Triazines

Keep exploring